Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?

The effect of serial in vitro haemodilution with maternal cerebrospinal fluid and crystalloid on thromboelastographic (TEG(®) ) blood coagulation parameters, and the implications for epidural blood patching.

Anaesthesia·2014

The reliability of the modified lower extremity functional scale among adults living with HIV on antiretroviral therapy, in Rwanda, Africa.

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance·2014

Endoscopy supply water and final rinse testing: five years of experience.

The Journal of hospital infection·2014

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.

Lung cancer (Amsterdam, Netherlands)·2014

Health risk estimates for groundwater and soil contamination in the Slovak Republic: a convenient tool for identification and mapping of risk areas.

Environmental geochemistry and health·2014

HOW TO…: Use Videodiscs in Medical Education, Part 1.

Medical teacher·2014

Enteric viruses in HIV-related diarrhoea.

Molecular medicine today·2000

Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy.

Molecular medicine today·2000

Mining bacterial genomes for antimicrobial targets.

Molecular medicine today·2000

The adenomatous polyposis coli (APC) tumour suppressor--genetics, function and disease.

Molecular medicine today·2000

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

European journal of nuclear medicine and molecular imaging·2026

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Gut·2026

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Journal of Crohn's & colitis·2026

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Biochimica et biophysica acta. Reviews on cancer·2026

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Biochimica et biophysica acta. Reviews on cancer·2026

Related Experiment Videos

Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?

Related Concept Videos

The effect of serial in vitro haemodilution with maternal cerebrospinal fluid and crystalloid on thromboelastographic (TEG(®) ) blood coagulation parameters, and the implications for epidural blood patching.

The reliability of the modified lower extremity functional scale among adults living with HIV on antiretroviral therapy, in Rwanda, Africa.

Endoscopy supply water and final rinse testing: five years of experience.

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.

Health risk estimates for groundwater and soil contamination in the Slovak Republic: a convenient tool for identification and mapping of risk areas.

HOW TO…: Use Videodiscs in Medical Education, Part 1.

Enteric viruses in HIV-related diarrhoea.

Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy.

Mining bacterial genomes for antimicrobial targets.

The adenomatous polyposis coli (APC) tumour suppressor--genetics, function and disease.

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Related Experiment Videos

Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?

Related Concept Videos

Related Articles